BA2

Ginkgo Bioworks and XWELL Implement Expanded CDC Traveler-based Genomic Surveillance Program to Test for More than 30 Known Pathogens

Retrieved on: 
Monday, November 6, 2023
RSV, Air travel, Traveler, Ginkgo Bioworks, NYSE, SARS-CoV-2, BA2, Genomics, Omicron, JFK, Biosecurity, Virus, United, Volunteering, DNA, CDC, World Health Organization, COVID-19, TGS, BA3, Bacteria, Collection, Airport, XBB, Vaccine

The partners continue to help the CDC grow TGS’s capabilities to detect pathogens as early as possible, allowing for the best public health response.

Key Points: 
  • The partners continue to help the CDC grow TGS’s capabilities to detect pathogens as early as possible, allowing for the best public health response.
  • The program expansion will launch at four of the program’s seven major international airports (New York, JFK, San Francisco, Boston, and Washington DC, Dulles).
  • The expansion will enable the program’s ability to monitor and change focus as needed to identify priority pathogens.
  • We thank the volunteers who elect to swab their noses in service to our national security and public health.”

Ginkgo Bioworks and XWELL Implement Expanded CDC Traveler-based Genomic Surveillance Program to Test for More than 30 Known Pathogens

Retrieved on: 
Monday, November 6, 2023
RSV, Air travel, Traveler, Ginkgo Bioworks, NYSE, SARS-CoV-2, BA2, Genomics, Omicron, JFK, Biosecurity, Virus, United, Volunteering, DNA, CDC, World Health Organization, COVID-19, TGS, BA3, Bacteria, Public, Collection, Airport, XBB, Vaccine

BOSTON, Nov. 6, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and XWELL, Inc. (Nasdaq: XWEL) today announced they are expanding their work with the U.S. Centers for Disease Control and Prevention's (CDC's) Traveler-based Genomic Surveillance program (TGS) to test for more than 30 additional priority pathogens, in addition to SARS-CoV-2. TGS is a flexible, multimodal platform that consists of three complementary approaches of sample collection from arriving international travelers at U.S. airports, including voluntary nasal swabbing, aircraft wastewater, and airport wastewater sampling to enhance early detection of new SARS-CoV-2 variants and other pathogens, and fills gaps in global surveillance.

Key Points: 
  • The partners continue to help the CDC grow TGS's capabilities to detect pathogens as early as possible, allowing for the best public health response.
  • The program expansion will launch at four of the program's seven major international airports (New York, JFK, San Francisco, Boston, and Washington DC, Dulles).
  • The TGS program can augment global surveillance systems, especially as testing and sequencing information become limited as Covid-19 monitoring wanes.
  • We thank the volunteers who elect to swab their noses in service to our national security and public health."

Equinix to Build New Data Center in Barcelona--A Growing Connectivity Hub of the Mediterranean

Retrieved on: 
Thursday, February 16, 2023
City Council of Barcelona, 1995 Barcelona City Council election, Biophysical environment, Medusa, Tourism, BA2, Certification, HP, EQIX, Emerging market, Microsoft, Software, Colt, Growth, Colt Technology Services, Ubisoft, Equinix, Digital, BA1, LEED, Video game, Amazon, Mediterranean Sea, Airbnb

The new site will serve as a strategic connection point for data communications between Europe, Africa and the Middle East, with Barcelona quickly becoming a vital subsea hub.

Key Points: 
  • The new site will serve as a strategic connection point for data communications between Europe, Africa and the Middle East, with Barcelona quickly becoming a vital subsea hub.
  • This substantial digital connectivity will be further bolstered by Equinix's global platform of more than 245 data centers, which includes key Mediterranean metros such as Bordeaux, Genoa, Lisbon and Milan.
  • "Spain is an increasingly important digital market and a solid port in the Mediterranean connectivity map.
  • Hosting 45+ network carriers, these expansive facilities provide connectivity to the CATNIX regional internet exchange as well as the Equinix Internet Exchange®.

EnGeneIC’s second generation COVID-19 vaccine protects against all variants

Retrieved on: 
Tuesday, June 28, 2022
John Engen, Patient, Antibody, Sydney Adventist Hospital, Chief executive officer, GLOBE, COVID-19, Population, Cancer, Omicron, BA2, Disease, McDiarmid, Immune system, Infection, EDV, Sirna, Toxicity, Temperature, Vaccine, Safety, Immunity, Volunteering, Diabetes, Rheumatoid arthritis, Pharmaceutical industry, Ethics

SYDNEY, Australia, June 28, 2022 (GLOBE NEWSWIRE) -- The worlds first COVID-19 vaccine to offer immunity against all variants is one step closer.

Key Points: 
  • SYDNEY, Australia, June 28, 2022 (GLOBE NEWSWIRE) -- The worlds first COVID-19 vaccine to offer immunity against all variants is one step closer.
  • Clinical trials have shown the novel vaccine works by stimulating a completely different immune pathway from other vaccines, producing high affinity antibodies that neutralise all COVID-19 variants.
  • Australian Biopharma company EnGeneIC is currently conducting trials of its groundbreaking vaccine in Sydney and Melbourne.
  • Were very excited by these results and to be part of EnGeneICs anti-COVID-19 vaccine trial, particularly in light of its being an Australian innovation, he said.

SpeeDx Expand COVID-19 Diagnostics to Include Self-Collected Samples

Retrieved on: 
Thursday, April 21, 2022
Health, Infectious Diseases, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, BA1, Workflow, Real-time, Population, COVID-19, Genetic distance, STI, Respiratory syncytial virus, Mycoplasma pneumoniae, Automation, Growth, Review, Technology, GLAD-PCR assay, Clarinox Technologies Pty Ltd, Respiratory disease, Laboratory, Saliva, TGA, BA2, Mycoplasma, Partnership, Omicron, Severe acute respiratory syndrome coronavirus 2, Assessment, Vaccine

A preferred sample type for self-collection and compliance testing programs, the saliva claim will expand the utility of the SpeeDx COVID-19 workflow, and in partnership with the Molgen range of automation, will further support ultra-high throughput testing markets.

Key Points: 
  • A preferred sample type for self-collection and compliance testing programs, the saliva claim will expand the utility of the SpeeDx COVID-19 workflow, and in partnership with the Molgen range of automation, will further support ultra-high throughput testing markets.
  • Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe.
  • SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management.
  • Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.